Here's Why Parexel International Shares Fell as Much as 15.5% Today

This post was originally published on this site

Images

What happened

Biopharma outsourcing services company PAREXEL International (NASDAQ:PRXL) was down as much as 15.5% this morning after filing a notice with the Securities and Exchange Commission that it would not be able to file its most recent quarterly report on time. Why not? It discovered that changes needed to be made to its fiscal 2017 first-quarter earnings, which ended on Sept. 30. That's usually an awful sign — and investors are rightfully dismayed by the surprise news.

So what

The filing was an NT 10-Q, or a non-timely 10-Q notice, which alerts the SEC and shareholders that a company will not be able to submit its quarterly report, or 10-Q, within the usual allotment of time following the public announcement of quarterly earnings. That can happen for any number of reasons, but they're usually all red flags.

PAREXEL International's delay came after it discovered that it was not properly accounting for revenue and earnings from prior periods, including the most recent quarter that ended on Sept. 30. The filing shows that the company will be adjusting revenue $6.7 million lower and earnings per share (EPS) $0.08 lower from numbers first announced for its fiscal 2017 first quarter. Worse, the correction comes as the company's growth has been slipping this calendar year.

While that's not good news — and investors still don't know what adjustments will be made to quarterly numbers further in the past — the corrections included in the filing are relatively minor as far as what can usually go horribly wrong when a company files an NT 10-Q. PAREXEL International reported quarterly revenue of $580.7 million, so the adjustment amounts to a difference of just 1.2%. The EPS correction packs a bigger punch, as it lowers the reported figure of $0.75 to just $0.67, or a difference of 10.7%. 

Now what

This does not appear to be a worst-case scenario. PAREXEL International has a business that has been verified by the market, is still profitable, is still maintaining healthy growth in the top line, and has several favorable trends in the biopharma industry available to exploit. But if substantial other corrections are made to previous periods, then it may turn out that the company's business is not as profitable as investors had thought. That would be met with a lower stock price, which doesn't get better considering the stock is already at 52-week lows and down 19% year to date. Right now, there's no way to know the full impact until the delayed 10-Q is filed with the SEC, but investors don't appear to be taking any chances.

Maxx Chatsko has no position in any stocks mentioned. Follow him on Twitter to keep up with developments in engineered biology and materials science.

The Motley Fool owns shares of Parexel International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.